Pharmacogenetics of EGFR in lung cancer: Perspectives and clinical applications

Pharmacogenomics

Volumn 13, Issue 7, 2012, Pages 789-802

  Mayo, Clara ^a   Bertran Alamillo, Jordi ^a   Molina Vila, Miguel Ángel ^a   Giménez Capitán, Ana ^a   Costa, Carlota ^a   Rosell, Rafael ^a,b  

^a INSTITUT UNIVERSITARI DEXEUS   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Tyrosine kinase inhibitors

Indexed keywords

4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; AFATINIB; ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; I KAPPA B KINASE; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; NERATINIB; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PLATINUM COMPLEX; PROTEIN KINASE B; SCATTER FACTOR; SILIBININ; SOMATOMEDIN C RECEPTOR; UNINDEXED DRUG;

CANCER REGRESSION; CANCER RESISTANCE; DRUG RESPONSE; DRUG SENSITIVITY; EGFR GENE; EPITHELIAL MESENCHYMAL TRANSITION; EXON; GENE; GENE AMPLIFICATION; GENE DELETION; GENE DOSAGE; GENE MUTATION; GENE OVEREXPRESSION; GENETIC VARIABILITY; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; NONHUMAN; ONCOGENE; PHARMACOGENETICS; PROGRESSION FREE SURVIVAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; UNSPECIFIED SIDE EFFECT;

BIOMARKERS, PHARMACOLOGICAL; CARCINOMA, NON-SMALL-CELL LUNG; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; PHARMACOGENETICS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84861167686     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.54     Document Type: Review

References (85)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J. Clin. 58(2), 71-96 (2008).
2. Gazdar AF. Personalized medicine and inhibition of EGFR signaling in lung cancer. N. Engl. J. Med. 361(10), 1018-1020 (2009).
3. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 12(2), 175-180 (2011).
4. Cataldo VD, Gibbons DL, Perez-Soler R, Quintas-Cardama A. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N. Engl. J. Med. 364(10), 947-955 (2011).
5. Costa DB, Kobayashi S, Tenen DG, Huberman MS. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer 58(1), 95-103 (2007). (Pubitemid 47379970)
6. Rosell R, Moran T, Queralt C et al. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 361(10), 958-967 (2009).
7. Hammerman PS, Janne PA, Johnson BE. Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin. Cancer Res. 15(24), 7502-7509 (2009).
8. Engelman JA, Settleman J. Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr. Opin. Genet. Dev. 18(1), 73-79 (2008). (Pubitemid 351694445)
9. Rosell R, Molina MA, Costa C et al. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin. Cancer Res. 17(5), 1160-1168 (2011).
10. Bivona TG, Hieronymus H, Parker J et al. FAS and NF-kappaB signalling modulate dependence of lung cancers on mutant EGFR. Nature 471(7339), 523-526 (2011).
11. Reguart N, Cardona AF, Carrasco E et al. BRCA1: a new genomic marker for non-small-cell lung cancer. Clin. Lung Cancer 9(6), 331-339 (2008).
12. Sethi G, Ahn KS, Chaturvedi MM, Aggarwal BB. Epidermal growth factor (EGF) activates nuclear factor-kappaB through IkappaBalpha kinase-independent but EGF receptor-kinase dependent tyrosine 42 phosphorylation of IkappaBalpha. Oncogene 26(52), 7324-7332 (2007). (Pubitemid 350115978)
13. Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 28(suppl. 1), S24-S31 (2009).
14. Kumar A, Petri ET, Halmos B, Boggon TJ. Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J. Clin. Oncol. 26(10), 1742-1751 (2008).
15. Pao W, Iafrate AJ, Su Z. Genetically informed lung cancer medicine. J. Pathol. 223(2), 230-240 (2010).
16. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N. Engl. J. Med. 358(11), 1160-1174 (2008).
17. De Luca A, Normanno N. Predictive biomarkers to tyrosine kinase inhibitors for the epidermal growth factor receptor in non-small-cell lung cancer. Curr. Drug Targets 11(7), 851-864 (2010).
18. Gazdar AF, Minna JD. Deregulated EGFR signaling during lung cancer progression: mutations, amplicons, and autocrine loops. Cancer Prev. Res. (Phila.) 1(3), 156-160 (2008).
19. Ekstrand AJ, Sugawa N, James CD, Collins VP. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N-and/or C-terminal tails. Proc. Natl Acad. Sci. USA 89(10), 4309-4313 (1992).
20. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676), 1497-1500 (2004). (Pubitemid 38720929)
21. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350(21), 2129-2139 (2004). (Pubitemid 38637993)
22. Mitsudomi T, Kosaka T, Yatabe Y. Biological and clinical implications of EGFR mutations in lung cancer. Int J. Clin. Oncol. 11(3), 190-198 (2006). (Pubitemid 44087117)
23. Ji H, Li D, Chen L et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 9(6), 485-495 (2006). (Pubitemid 43832191)
24. Xin H, Herrmann A, Reckamp K et al. Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480. Cancer Res. 71(21), 6601-6610 (2011).
25. Rosell R, Viteri S, Molina MA, Benlloch S, Taron M. Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer. Curr. Opin. Oncol. 22(2), 112-120 (2010).
26. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361(10), 947-957 (2009).
27. Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 11(2), 121-128 (2010).
28. Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362(25), 2380-2388 (2010).
29. Zhou C, Wu Y-L, Chen G et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 12, 735-742 (2011).
30. Takano T, Fukui T, Ohe Y et al. EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. J. Clin. Oncol. 26(34), 5589-5595 (2008).
31. Sequist LV, Martins RG, Spigel D et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J. Clin. Oncol. 26(15), 2442-2449 (2008).
32. Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13(3), 239-246 (2012).
33. Gao G, Ren S, Li A et al. Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: a meta-analysis from 6 phase III randomized controlled trials. Int. J. Cancer doi:10.1002/ijc.27396 (2011) (Epub ahead of print).
34. Normanno N, De Luca A, Bianco C et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366(1), 2-16 (2006). (Pubitemid 43199589)
35. Cappuzzo F, Hirsch FR, Rossi E et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Natl Cancer Inst. 97(9), 643-655 (2005). (Pubitemid 40812628)
36. Hirsch FR, Varella-Garcia M, Bunn PA Jr et al. Molecular predictors of outcome with gefitinib in a Phase III placebo-controlled study in advanced non-small-cell lung cancer. J. Clin. Oncol. 24(31), 5034-5042 (2006). (Pubitemid 46631407)
37. Douillard JY, Shepherd FA, Hirsh V et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized Phase III INTEREST trial. J. Clin. Oncol. 28(5), 744-752 (2010).
38. Crino L, Cappuzzo F, Zatloukal P et al. Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, Phase II study. J. Clin. Oncol. 26(26), 4253-4260 (2008).
39. Brugger W, Triller N, Blasinska-Morawiec M et al. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 29(31), 4113-4120 (2011).
40. Yatabe Y, Takahashi T, Mitsudomi T. Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer. Cancer Res. 68(7), 2106-2111 (2008). (Pubitemid 351521782)
41. Hirsch FR, Varella-Garcia M, Dziadziuszko R et al. Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a Phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer. Clin. Cancer Res. 14(19), 6317-6323 (2008).
42. Fukuoka M, Wu YL, Thongprasert S et al. Biomarker analyses and final overall survival results from a Phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J. Clin. Oncol. 29(21), 2866-2874 (2011).
43. Pao W, Miller VA, Politi KA et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2(3), e73 (2005).
44. Kobayashi S, Boggon TJ, Dayaram T et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352(8), 786-792 (2005). (Pubitemid 40271173)
45. Yun CH, Mengwasser KE, Toms AV et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl Acad. Sci. USA 105(6), 2070-2075 (2008). (Pubitemid 351439466)
46. Blencke S, Ullrich A, Daub H. Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors. J. Biol. Chem. 278(17), 15435-15440 (2003). (Pubitemid 36799884)
47. Engelman JA, Mukohara T, Zejnullahu K et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J. Clin. Invest. 116(10), 2695-2706 (2006). (Pubitemid 44511633)
48. Kuang Y, Rogers A, Yeap BY et al. Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. Clin. Cancer Res. 15(8), 2630-2636 (2009).
49. Arcila ME, Oxnard GR, Nafa K et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin. Cancer Res. 17(5), 1169-1180 (2011).
50. Garcia-Olive I, Monso E, Andreo F et al. Endobronchial ultrasound-guided transbronchial needle aspiration for identifying EGFR mutations. Eur. Respir. J. 35(2), 391-395 (2010).
51. Su KY, Chen HY, Li KC et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J. Clin. Oncol. 30(4), 433-440 (2012).
52. Engelman JA, Zejnullahu K, Mitsudomi T et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316(5827), 1039-1043 (2007). (Pubitemid 46799492)
53. Yano S, Wang W, Li Q et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res. 68(22), 9479-9487 (2008).
54. Sequist LV, Waltman BA, Dias-Santagata D et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 3(75), 75ra26 (2011).
55. Yauch RL, Januario T, Eberhard DA et al. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin. Cancer Res. 11(24 Pt 1), 8686-8698 (2005). (Pubitemid 43005918)
56. Suda K, Tomizawa K, Fujii M et al. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. J. Thorac. Oncol. 6(7), 1152-1161 (2011).
57. Yao Z, Fenoglio S, Gao DC et al. TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc. Natl Acad. Sci. USA 107(35), 15535-15540 (2010).
58. Yamasaki F, Johansen MJ, Zhang D et al. Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. Cancer Res. 67(12), 5779-5788 (2007). (Pubitemid 46985011)
59. Guix M, Faber AC, Wang SE et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J. Clin. Invest. 118(7), 2609-2619 (2008). (Pubitemid 351949788)
60. Chmielecki J, Foo J, Oxnard GR et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci. Transl. Med. 3(90), 90ra59 (2011).
61. Chaft JE, Oxnard GR, Sima CS et al. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib. Clin. Cancer Res. 17(19), 6298-6303 (2011).
62. Zhou W, Ercan D, Chen L et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 462(7276), 1070-1074 (2009).
63. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 7(3), 169-181 (2007).
64. Yap TA, Vidal L, Adam J et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J. Clin. Oncol. 28(25), 3965-3972 (2010).
65. Sequist LV, Besse B, Lynch TJ et al. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a Phase II trial in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 28(18), 3076-3083 (2010).
66. Rho JK, Choi YJ, Jeon BS et al. Combined treatment with silibinin and epidermal growth factor receptor tyrosine kinase inhibitors overcomes drug resistance caused by T790M mutation. Mol. Cancer Ther. 9(12), 3233-3243 (2010).
67. Maheswaran S, Sequist LV, Nagrath S et al. Detection of mutations in EGFR in circulating lung-cancer cells. N. Engl. J. Med. 359(4), 366-377 (2008).
68. Prudkin L, Tang X, Wistuba II. Germ-line and somatic presentations of the EGFR T790M mutation in lung cancer. J. Thorac. Oncol. 4(1), 139-141 (2009).
69. Inukai M, Toyooka S, Ito S et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res. 66(16), 7854-7858 (2006). (Pubitemid 44299146)
70. Janku F, Garrido-Laguna I, Petruzelka LB et al. Novel therapeutic targets in non-small cell lung cancer. J. Thorac. Oncol. 6(9), 1601-1612 (2011).
71. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. Cancer 9(8), 550-562 (2009).
72. Carcereny E, Molina MA, Sanchez JJ et al. Mutations of the catalytic subunit alpha of PI3K (PIK3CA) in erlotinib-treated non-small-cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations J. Clin. Oncol. (Suppl. abstract 7588), 29 (2011).
73. Chaft JE, Arcila ME, Paik PK et al. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. Mol. Cancer Ther. 11(2), 485-491 (2011).
74. Pao W, Wang TY, Riely GJ et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2(1), e17 (2005).
75. Massarelli E, Varella-Garcia M, Tang X et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin. Cancer Res. 13(10), 2890-2896 (2007). (Pubitemid 46849563)
76. Schmid K, Oehl N, Wrba F et al. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin. Cancer Res. 15(14), 4554-4560 (2009).
77. Shrivastav M, De Haro LP, Nickoloff JA. Regulation of DNA double-strand break repair pathway choice. Cell Res. 18(1), 134-147 (2008).
78. Taron M, Rosell R, Felip E et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum. Mol. Genet. 13(20), 2443-2449 (2004). (Pubitemid 39377848)
79. Rosell R, Perez-Roca L, Sanchez JJ et al. Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PLoS ONE 4(5), e5133 (2009).
80. Hegan DC, Lu Y, Stachelek GC et al. Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130. Proc. Natl Acad. Sci. USA 107(5), 2201-2206 (2010).
81. Lee SG, Su ZZ, Emdad L, Sarkar D, Franke TF, Fisher PB. Astrocyte elevated gene-1 activates cell survival pathways through PI3K-Akt signaling. Oncogene 27(8), 1114-1121 (2008). (Pubitemid 351253177)
82. Santarpia M, Magri I, Sanchez-Ronco M et al. mRNA expression levels and genetic status of genes involved in the EGFR and NF-kappaB pathways in metastatic non-small-cell lung cancer patients. J. Transl. Med. 9, 163 (2011).
83. Audeh MW, Carmichael J, Penson RT et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376(9737), 245-251 (2010).
84. Tutt A, Robson M, Garber JE et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376(9737), 235-244.
85. Naumov GN, Nilsson MB, Cascone T et al. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin. Cancer Res. 15(10), 3484-3494 (2009).